Login to Your Account



European biopharma funding falls to $3.8B in 2016 as IPOs lag

By Cormac Sheridan
Staff Writer

Friday, January 6, 2017

DUBLIN – European biotech firms engaged in drug development raised an aggregate $3.789 billion in equity funding during 2016, down almost 23 percent on the previous year's total of $4.913 billion.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription